Get the Stockscreener App
6.17
0.64%
-0.04
After Hours:
6.30
0.13
+2.11%
Y Mabs Therapeutics Inc Stock (YMAB) Latest News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Y-Mabs Therapeutics Inc (YMAB) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference - The Manila Times
Cancer Treatment Pioneer Y-mAbs Takes Center Stage at Major Healthcare Conference - StockTitan
Analytical Overview: Y-Mabs Therapeutics Inc (YMAB)’s Ratios Tell a Financial Story - The Dwinnex
YmAbs Therapeutics (YMAB) Loses -25.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
A stock that deserves closer examination: Y-Mabs Therapeutics Inc (YMAB) - US Post News
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
YmAbs Therapeutics (YMAB) Loses -26.93% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
YMAB stock touches 52-week low at $6 amid challenging year - MSN
Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting - The Manila Times
Groundbreaking Cancer Treatment Data: Y-mAbs' GD2-SADA Shows Remarkable Preclinical Results - StockTitan
Y-mAbs Therapeutics' SWOT analysis: innovative cancer therapy stock faces growth hurdles - MSN
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Position Boosted by JPMorgan Chase & Co. - Defense World
Y-mAbs Therapeutics’ SWOT analysis: innovative cancer therapy stock faces growth hurdles - Investing.com Nigeria
(YMAB) Trading Report - Stock Traders Daily
Y-mAbs Therapeutics: Finding Direction Through The Murk Of Clinical Trials - Seeking Alpha
Cantor Fitzgerald Weighs in on YMAB FY2025 Earnings - Defense World
Cantor Fitzgerald Predicts YMAB FY2025 Earnings - MarketBeat
Contrasting Lotus Pharmaceuticals (OTCMKTS:LTUS) and Y-mAbs Therapeutics (NASDAQ:YMAB) - Defense World
Layoff Tracker: Notch Therapeutics to ‘Significantly Reduce’ Workforce - BioSpace
Barclays PLC Increases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics Releases Corporate Overview PresentationOn January 13, 2025, Y-mAbs Therapeutics, Inc. disclosed a corporate overview presentation on its investor relations website, https://ir.ymabs.com. The presentation is intended for investor - Defense World
Y-mAbs Therapeutics’ (YMAB) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Y-mAbs Therapeutics Updates on Business and Clinical Trials - TipRanks
Y-mAbs Therapeutics (NASDAQ:YMAB) Given "Buy" Rating at HC Wainwright - MarketBeat
Y-mAbs Therapeutics Announces Business Realignment Plan and Preliminary 2024 Financial ResultsOn January 6, 2025, Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) revealed a business realignment plan aimed at maximizing operational efficiencies. The p - Defense World
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns Outperform Rating from Wedbush - Defense World
Y-mAbs Therapeutics Announces Strategic Business Realignment - Yahoo Finance
Y-mAbs Therapeutics (NASDAQ:YMAB) Earns "Outperform" Rating from Wedbush - MarketBeat
Benign Growth For Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Underpins Stock's 26% Plummet - Simply Wall St
Correcting & ReplacingY-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Reports $88M Revenue, Restructures with Focus on Radiopharmaceuticals and DANYELZA Growth - StockTitan
Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities - Business Upturn
Y-mAbs Therapeutics, Inc. Announces Executive Changes - Marketscreener.com
Y-mAbs Appoints Doug Gentilcore as Senior Vice President, Head of DANYELZA Business Unit - citybiz
Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit - The Manila Times
Y-mAbs Strengthens DANYELZA Team with Industry Veteran Doug Gentilcore as Business Unit Head - StockTitan
Y-mAbs Provides Strategic Business Update and 2025 Priorities - The Manila Times
Y-mAbs Therapeutics Hits $88M Revenue Target, Unveils Strategic Split Into Two Business Units - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Given Average Recommendation of “Buy” by Analysts - Defense World
Analysts Set Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Price Target at $20.89 - MarketBeat
Y-mAbs Therapeutics price target lowered to $14 from $17 at BofA - Yahoo Finance
When (YMAB) Moves Investors should Listen - Stock Traders Daily
Principal Financial Group Inc. Makes New Investment in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by Geode Capital Management LLC - Defense World
Barclays PLC Purchases 56,244 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Acquired by State Street Corp - Defense World
State Street Corp Grows Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - MarketBeat
Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Y-mAbs Therapeutics to Present at J.P. Morgan Healthcare Conference 2025: Cancer Treatment Innovation Spotlight - StockTitan
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
We're Hopeful That Y-mAbs Therapeutics (NASDAQ:YMAB) Will Use Its Cash Wisely - Yahoo Finance
0.82%
0.53%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):